Tonix Pharmaceuticals Advances Lyme Disease Prevention Candidate with Phase 2 Plans — Tonix Pharmaceuticals Holding Corp.

Event summary

Tonix Pharmaceuticals presented Phase 1 data for TNX-4800 at the Ticks and Tickborne Diseases Symposium on April 29, 2026.
The company plans to initiate a randomized, double-blind, placebo-controlled, adaptive Phase 2 field study in the first half of 2027, pending FDA agreement.
TNX-4800 is designed to provide protection against Lyme disease within two days of the first dose for the peak U.S. Lyme season.
The Phase 2 study will test a two-dose regimen of TNX-4800 subcutaneous with an initial Spring dose followed by a Summer booster two months later.

The big picture

Tonix Pharmaceuticals is advancing its TNX-4800 candidate for Lyme disease prevention, aiming to address a significant unmet medical need in the U.S. where no FDA-approved vaccines or prophylactics currently exist. The company's strategy focuses on leveraging monoclonal antibody technology to provide immediate protection, potentially overcoming adherence challenges associated with traditional vaccine schedules.

What we're watching

Regulatory Alignment: Whether Tonix can secure FDA agreement for the adaptive Phase 2 field study design by early Q3 2026.
Clinical Efficacy: The pace at which TNX-4800 demonstrates efficacy in preventing Lyme disease during the six-month primary endpoint period.
Market Differentiation: How TNX-4800's rapid protection and simplified dosing regimen will position it against other Lyme disease prevention candidates.